AstraZeneca says Fasenra fails to meet one trial endpoint
AstraZeneca
10,292.00p
16:49 14/11/24
1.46%
148.00p
AstraZeneca said its Fasenra treatment for a rare inflammatory disease of the oesophagus failed to meet one of the two dual-primary endpoints in a phase 3 trial.
FTSE 100
8,071.19
16:49 14/11/24
n/a
n/a
FTSE 350
4,459.02
16:38 14/11/24
n/a
n/a
FTSE All-Share
4,417.25
16:54 14/11/24
n/a
n/a
Pharmaceuticals & Biotechnology
19,794.96
16:38 14/11/24
0.96%
187.95
Fasenra demonstrated a statistically significant improvement in histological disease remission, but not a change in dysphagia symptoms, compared to placebo, in patients with Eosinophilic oesophagitis (EoE) aged 12 or older.
EoE is a rare, progressive, chronic inflammatory disease of the oesophagus currently believed to be characterised by the abnormal presence of eosinophils, a type of white blood cell, in the inner lining of the esophagus. Patients experience difficulty with swallowing (dysphagia), pain, food getting stuck and anxiety.
Reporting by Frank Prenesti for Sharecast.com